Better resolution of nail psoriasis seen with ixekizumab than adalimumab
Click Here to Manage Email Alerts
Ixekizumab showed a significantly higher rate of resolving nail psoriasis compared with adalimumab, according to a study poster presented at the American Academy of Dermatology virtual meeting.
A post hoc subgroup analysis of the SPIRIT-H2H study included 100 subjects with moderate to severe psoriasis with a Psoriasis Area and Severity Index score of 12 or higher, a static Physician’s Global Assessment score of 3 or higher and Body Surface Area involvement of 10% or more, while 78 subjects had nail psoriasis with a baseline Nail Psoriasis Severity Index (NAPSI) fingernails score of 1 or higher.
At week 16, 59.5% of those treated with ixekizumab had complete resolution of nail psoriasis compared with 48.8% of those treated with adalimumab. Those percentages rose to 64.9% and 58.5%, respectively, at week 16 and 80% and 52.5%, respectively, at week 24.
The difference between the two groups in least squares mean change in NAPSI baseline score was –4.4 at week 24.
“In this post hoc analysis, [ixekizumab] showed significantly higher rates of complete resolution of nail involvement than [adalimumab] at week 24, confirming the established efficacy of [ixekizumab] in nail psoriasis,” the study authors wrote.
Collapse
Smith SD, et al. Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate-to-severe psoriasis: 24-week results from a multicentre, randomised, open-label, rater-blinded study (SPIRIT-H2H). Presented at: AAD VMX; June 12-14, 2020 (virtual meeting).
Read more about
Click Here to Manage Email Alerts